Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10

Reports Q4 revenue $45.891M, consensus $50.7M. “We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high for Yupelri brand-level profitability, and reaching $75 million in key sales-based milestones. These results highlight the strength and durability of our commercial asset, Yupelri, our commitment to operating with financial and operational discipline, and the strength of our balance sheet,” said Rick E Winningham, Chief Executive Officer of Theravance Biopharma (TBPH). “Since announcing the CYPRESS study results earlier this month, we have made progress implementing an organizational restructuring to streamline costs and align resources with the commercial opportunity ahead of Yupelri, We are confident that these actions, paired with the important work that the Board’s Strategic Review Committee is doing to evaluate opportunities available to the Company, will enable Theravance to deliver on our goal of maximizing value for shareholders.”